USD
+$0.00
(+0.00%
)At Close (As of Nov 28, 2025)
$15.18M
Market Cap
-
P/E Ratio
-6
EPS
$14.80
52 Week High
$2.30
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $20M |
| Total Revenue | $29M |
| Cost Of Revenue | $9.3M |
| Costof Goods And Services Sold | $9.3M |
| Operating Income | -$20M |
| Selling General And Administrative | $18M |
| Research And Development | $9.1M |
| Operating Expenses | $40M |
| Investment Income Net | - |
| Net Interest Income | -$7.3M |
| Interest Income | $1.8M |
| Interest Expense | $9.1M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $4.1M |
| Income Before Tax | -$9.2M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$9.2M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$147K |
| Ebitda | $3.9M |
| Net Income | -$9.2M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $20M |
| Total Revenue | $29M |
| Cost Of Revenue | $9.3M |
| Costof Goods And Services Sold | $9.3M |
| Operating Income | -$20M |
| Selling General And Administrative | $18M |
| Research And Development | $9.1M |
| Operating Expenses | $40M |
| Investment Income Net | - |
| Net Interest Income | -$7.3M |
| Interest Income | $1.8M |
| Interest Expense | $9.1M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $4.1M |
| Income Before Tax | -$9.2M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$9.2M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$147K |
| Ebitda | $3.9M |
| Net Income | -$9.2M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
BioLineRx Ltd. is a clinical-stage biopharmaceutical company based in Hevel Modi'in, Israel, focused on developing innovative therapies primarily in the oncology sector. With a robust pipeline of drug candidates targeting significant unmet medical needs in cancer treatment and other serious health conditions, BioLineRx is committed to advancing research and improving patient outcomes. The company employs cutting-edge technologies and engages in strategic partnerships to enhance its R&D capabilities, positioning itself as a critical player in the biopharmaceutical landscape, while also delivering potential value for institutional investors.